Pre-Open Stock Movers:

CTI BioPharma Corp. (Nasdaq: CTIC) 54% HIGHER; announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 Ã-109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.

GoodRx Holdings, Inc. (NASDAQ: GDRX) 31.8% LOWER; reported Q4 EPS of $0.09, $0.01 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $213.3 million versus the consensus estimate of $217.53 million. GoodRx Holdings, Inc. sees Q1 2022 revenue of ~$200 million, versus the consensus of $227.92 million. For the year, the company sees ~23% year-over-year growth.

Vroom (NASDAQ: VRM) 20.2% LOWER; reported Q4 EPS of ($0.94), $0.17 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $934.49 million versus the consensus estimate of $901.49 million.

Ambarella (NASDAQ: AMBA) 20% LOWER; reported Q4 EPS of $0.45, $0.03 better than the analyst estimate of $0.42. Revenue for the quarter came in at $90.2 million versus the consensus estimate of $90.16 million. Ambarella sees Q1 2023 revenue of $88.5-91.5 million, versus the consensus of $90.88 million.

BigCommerce (NASDAQ: BIGC) 20% LOWER; reported Q4 EPS of ($0.17), $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $64.9 million versus the consensus estimate of $61.82 million. BigCommerce sees Q1 2022 revenue of $61.9-65.1 million, versus the consensus of $63.83 million. BigCommerce sees FY2022 revenue of $271.6-283.6 million, versus the consensus of $277.79 million.

Target (NYSE: TGT) 14% HIGHER; reported Q4 EPS of $3.19, $0.33 better than the analyst estimate of $2.86. Revenue for the quarter came in at $31 billion versus the consensus estimate of $31.41 billion. Comparable sales grew 8.9 percent, on top of 20.5 percent in Q4 2020.

3D Systems (NYSE: DDD) 13.7% HIGHER; reported Q4 EPS of $0.09, $0.05 better than the analyst estimate of $0.04. Revenue for the quarter came in at $150.9 million versus the consensus estimate of $144.18 million. 3D Systems sees 2022 revenue of $570-630 million, versus the consensus of $573.5 million.

Lucid Group (NASDAQ: LCID) 13.4% LOWER; reported Q4 EPS of ($0.64), $0.29 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $26.4 million versus the consensus estimate of $36.74 million. Customer reservations now exceed 25,000, reflecting potential sales of more than $2.4B

Workday (NASDAQ: WDAY) 7.8% HIGHER; reported Q4 EPS of $0.78, $0.07 better than the analyst estimate of $0.71. Revenue for the quarter came in at $1.38 billion versus the consensus estimate of $1.36 billion.

Baidu (NASDAQ: BIDU) 6.6% HIGHER; reported Q4 EPS of $1.82, $0.49 better than the analyst estimate of $1.33. Revenue for the quarter came in at $5.19 billion versus the consensus estimate of $5.06 billion.

Albertsons Companies, Inc. (NYSE: ACI) 6.4% HIGHER; The Board of Directors announced today that it has commenced a Board-led review of potential strategic alternatives aimed at enhancing Albertsons growth and maximizing shareholder value. The review will include an assessment of various balance sheet optimization and capital return strategies, potential strategic or financial transactions and development of other strategic initiatives to complement Albertsons existing businesses, as well as responding to inquiries.

Kroger (NYSE: KR) 2.7% HIGHER; Telsey analyst Joseph Feldman upgraded from Market Perform to Outperform with a price target of $54.00 (from $47.00).

Zoom (NASDAQ: ZM) 2.7% LOWER; reported Q4 EPS of $1.29, $0.24 better than the analyst estimate of $1.05. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.05 billion. Zoom sees Q1 2023 EPS of $0.86-$0.88, versus the consensus of $1.05. Zoom sees Q1 2023 revenue of $1.07-1.075 billion, versus the consensus of $1.1 billion. Zoom sees FY2023 EPS of $3.45-$3.51, versus the consensus of $4.40. Zoom sees FY2023 revenue of $4.53-4.55 billion, versus the consensus of $4.71 billion.

Kohl's (NYSE: KSS) 1.6% HIGHER; reported Q4 EPS of $2.20, $0.06 better than the analyst estimate of $2.14. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.57 billion. Kohl's sees FY2022 EPS of $7.00-$7.50, versus the consensus of $6.54. Expects full year 2022 net sales to increase 2% to 3% as compared to 2021.